SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-117734
Filing Date
2021-04-15
Accepted
2021-04-15 16:05:57
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFA14A d131543ddefa14a.htm DEFA14A 33012
2 GRAPHIC g131543gra001.jpg GRAPHIC 2179
3 GRAPHIC g131543gra003.jpg GRAPHIC 1250
4 GRAPHIC g131543gra004.jpg GRAPHIC 900
5 GRAPHIC g131543snap0002.jpg GRAPHIC 1277
6 GRAPHIC g131543snap0006.jpg GRAPHIC 881
7 GRAPHIC g131543snap0007.jpg GRAPHIC 1175
  Complete submission text file 0001193125-21-117734.txt   45639
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38871 | Film No.: 21828549
SIC: 2834 Pharmaceutical Preparations